Paresh Malhotra

@pareshmalhotra.bsky.social

Cognitive Neurologist; Head of #Neurology @ Imperial College London; NIHR RDN National Specialty Lead, #Dementia & #Neurodegeneration; Trustee @ Alzheimer’s Society; Looking after patients with, and carrying out research into, Dementia. Views my own.

Among patients with newly diagnosed relapsing multiple sclerosis, rituximab was noninferior to ocrelizumab in preventing new or enlarging lesions on MRI. The risk of serious adverse events was similar in the two groups. Full OVERLORD-MS trial results and Research Summary: https://nej.md/3QJuaep

This image is from a Research Summary published in the New England Journal of Medicine, comparing rituximab and ocrelizumab for relapsing multiple sclerosis. It features participant details: 216 adults, mean age 37, with a gender distribution of 70% men and 30% women; 132 received rituximab while 84 received ocrelizumab. Illustrations depict a conceptual representation of relapsing multiple sclerosis. A note encourages further reading at NEJM.org.

On our 250th birthday, celebrating the contribution of immigrants and international collaboration —46% of people with doctoral-level degrees working in US science and engineering fields are foreign-born

BildBild

12 June 1929 | A German Jewish girl, Anne Frank, was born in Frankfurt. In 1942, on her 13th birthday, she received an empty diary. She perished in Bergen-Belsen concentration camp in 1945. 'Human greatness does not lie in wealth or power, but in character & goodness.' (A.Frank)

Anne Frank seated at a desk with an open book and a pen, looking directly at the camera, with a bottle of ink by her side.

Really happy to share the paper describing drug repurposing pipeline for an upcoming platform trial in clinical #Alzheimers disease with candidate selection through multidisciplinary international panel chaired by @suzanne-reeves.bsky.social. alz-journals.onlinelibrary.wiley.com/share/SIZN3I...

Repurposed drug prioritization pipeline for a multi‐arm platform trial in clinical Alzheimer's disease

Reader environment loaded

alz-journals.onlinelibrary.wiley.com

Our researchers at the UK DRI at Edinburgh are featured on the BBC today, highlighting how AI is transforming the search for treatments for neurodegenerative conditions 👏 Thank you to Steve, who generously shared his story and why research gives him hope 💙 www.bbc.co.uk/news/article...

AI used to speed up search for motor neurone disease drugs

Researchers hope the work will help identify affordable, effective drugs to treat conditions like MND.

bbc.co.uk

Do brain circuits really sit in a 'soup' of neuromodulators? Are neurons like soggy bits of bread soaked in signaling factors? Is the whole brain just squelching around in one big pool of warm modulators?

I teach this in my IP law class b/c when asked in an interview who owned the patent, Salk replied: "Well, the people, I would say. There is no patent. Could you patent the sun?" He looked for vaccine solutions his entire life…including a quest for a vaccine to prevent HIV from becoming AIDS.

Dr. Todd Arrington@btarrington.bsky.social · 4mo ago

On this day 70 years ago-May 1, 1956-the polio vaccine was first made widely available to the public. The vaccine’s developer, Dr. Jonas Salk, did not patent the vaccine so that it would remain available to as many people as possible in the US and internationally. Image: Harvey Georges/AP.

A selection of participants from the REACT study at Imperial College London are attending initial clinics via Inuvi for tests that will make them 'trial-ready'. Funded by the Medical Research Council, the initiative supports the Dame Barbara Windsor Dementia Goals programme.